Poster
BLU-222, a potent and highly selective CDK2 inhibitor, demonstrated antitumor activity as monotherapy and as combination treatment in CCNE1-aberrant endometrial cancer models
Author
Nealia House
Condition
endometrial cancer
Drug target
CDK2
Drug moa
CDK2 inhibition
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-AACR-2024-BLU-222-CCNE1-Endometrial-Cancer-Models-Poster.pdf
1 organization
1 product
Product
BLU-222Organization
Blueprint Medicines